In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by special guests Bernard Rubin, D.O., MPH, chief medical officer of Progentec Diagnostics, and Melissa Munroe, M.D., Ph.D., chief scientific officer and principal investigator of Progentec Diagnostics. They discuss Mayo Clinic Laboratories’ suite of innovative lupus testing, offered in collaboration with Progentec Diagnostics, for patients affected by systemic lupus erythematosus (SLE).

Their discussion includes:

• The Progentec aiSLE® DX Lupus Flare Risk Index that uses an algorithm to calculate a flare risk index, which assigns a score based on a patient's risk of a forthcoming lupus flare.
• The Progentec aiSLE® DX Lupus Disease Activity Index that characterizes a patient’s current disease activity into low, moderate, or active states.
• How these two tests were developed and for whom they are recommended.
• Why these tests are a significant development and how they enhance the quality of life for patients living with SLE.